Skip header and navigation

Refine By

1642 records – page 1 of 165.

A 4-year, cluster-randomized, controlled childhood obesity prevention study: STOPP.

https://arctichealth.org/en/permalink/ahliterature99038
Source
Int J Obes (Lond). 2009 Apr;33(4):408-17
Publication Type
Article
Date
Apr-2009
Author
C. Marcus
G. Nyberg
A. Nordenfelt
M. Karpmyr
J. Kowalski
U. Ekelund
Author Affiliation
Division of Pediatrics, Karolinska Institutet, Department of Clinical Science, Intervention and Technology, National Childhood Obesity Centre, Stockholm, Sweden. claude.marcus@ki.se
Source
Int J Obes (Lond). 2009 Apr;33(4):408-17
Date
Apr-2009
Language
English
Publication Type
Article
Keywords
Anthropometry
Child
Cluster analysis
Female
Health Promotion - organization & administration
Humans
Longitudinal Studies
Male
Obesity - epidemiology - prevention & control
Overweight - epidemiology - prevention & control
Parents - psychology
Physical Fitness - psychology
Prevalence
Risk Reduction Behavior
School Health Services
Sweden - epidemiology
Abstract
OBJECTIVE: To assess the efficacy of a school-based intervention programme to reduce the prevalence of overweight in 6 to 10-year-old children. DESIGN: Cluster-randomized, controlled study. SUBJECTS: A total of 3135 boys and girls in grades 1-4 were included in the study. METHODS: Ten schools were selected in Stockholm county area and randomized to intervention (n=5) and control (n=5) schools. Low-fat dairy products and whole-grain bread were promoted and all sweets and sweetened drinks were eliminated in intervention schools. Physical activity (PA) was aimed to increase by 30 min day(-1) during school time and sedentary behaviour restricted during after school care time. PA was measured by accelerometry. Eating habits at home were assessed by parental report. Eating disorders were evaluated by self-report. RESULTS: The prevalence of overweight and obesity decreased by 3.2% (from 20.3 to 17.1) in intervention schools compared with an increase of 2.8% (from 16.1 to 18.9) in control schools (P
PubMed ID
19290010 View in PubMed
Less detail

12-month follow-up of an exploratory 'brief intervention' for high-frequency cannabis users among Canadian university students.

https://arctichealth.org/en/permalink/ahliterature124885
Source
Subst Abuse Treat Prev Policy. 2012;7:15
Publication Type
Article
Date
2012
Author
Benedikt Fischer
Wayne Jones
Paul Shuper
Jürgen Rehm
Author Affiliation
Centre for Applied Research in Mental Health and Addictions, Faculty of Health Sciences, Simon Fraser University, 2400, 515 West Hastings St,, Vancouver, BC, V6B 5K3, Canada. bfischer@sfu.ca
Source
Subst Abuse Treat Prev Policy. 2012;7:15
Date
2012
Language
English
Publication Type
Article
Keywords
Adolescent
Female
Follow-Up Studies
Health Promotion - methods
Humans
Male
Marijuana Smoking - epidemiology - prevention & control
Ontario - epidemiology
Outcome Assessment (Health Care)
Questionnaires
Risk Reduction Behavior
Young Adult
Abstract
One in three young people use cannabis in Canada. Cannabis use can be associated with a variety of health problems which occur primarily among intensive/frequent users. Availability and effectiveness of conventional treatment for cannabis use is limited. While Brief Interventions (BIs) have been shown to result in short-term reductions of cannabis use risks or problems, few studies have assessed their longer-term effects. The present study examined 12-month follow-up outcomes for BIs in a cohort of young Canadian high-frequency cannabis users where select short-term effects (3 months) had previously been assessed and demonstrated.
N=134 frequent cannabis users were recruited from among university students in Toronto, randomized to either an oral or a written cannabis BI, or corresponding health controls, and assessed in-person at baseline, 3-months, and 12-months. N=72 (54%) of the original sample were retained for follow-up analyses at 12-months where reductions in 'deep inhalation/breathholding' (Q=13.1; p
Notes
Cites: J Subst Abuse Treat. 2003 Jun;24(4):369-7612867212
Cites: Drug Alcohol Depend. 2004 Feb 7;73(2):109-1914725950
Cites: J Consult Clin Psychol. 2004 Jun;72(3):455-6615279529
Cites: J Subst Abuse Treat. 2004 Oct;27(3):197-21315501373
Cites: Addiction. 2005 Nov;100(11):1594-61016277622
Cites: Lancet. 2007 Jul 28;370(9584):319-2817662880
Cites: J Consult Clin Psychol. 2000 Oct;68(5):898-90811068976
Cites: Subst Use Misuse. 2000 Feb;35(3):421-3210714454
Cites: Subst Abus. 2007;28(3):7-3018077300
Cites: J Subst Abuse Treat. 2013 Jan;44(1):132-822520278
Cites: J Subst Abuse Treat. 2008 Jun;34(4):407-1417869051
Cites: Drug Alcohol Depend. 2009 Jan 1;99(1-3):280-9518929451
Cites: Int Rev Psychiatry. 2009 Apr;21(2):96-10319367503
Cites: Int J Drug Policy. 2009 Nov;20(6):458-6619362460
Cites: Can J Public Health. 2009 Mar-Apr;100(2):101-319839283
Cites: Int J Methods Psychiatr Res. 2010 Jun;19(2):110-2420506447
Cites: Can J Public Health. 2011 Sep-Oct;102(5):324-722032094
PubMed ID
22538183 View in PubMed
Less detail

1995 Canadian women's health test. Time to promote women's health.

https://arctichealth.org/en/permalink/ahliterature213284
Source
Can Fam Physician. 1996 Jan;42:13-5, 20-3
Publication Type
Article
Date
Jan-1996
Author
S. Wiesenberg
Source
Can Fam Physician. 1996 Jan;42:13-5, 20-3
Date
Jan-1996
Language
English
Publication Type
Article
Keywords
Adult
Aged
Canada
Family Practice
Female
Health Knowledge, Attitudes, Practice
Health promotion
Humans
Middle Aged
Physician's Role
Questionnaires
Women's health
Notes
Cites: CMAJ. 1992 Jun 15;146(12):2167-741308756
Cites: Can Fam Physician. 1994 May;40:861-4, 870-28038628
Cites: Can Fam Physician. 1994 May;40:900-58038635
Comment In: Can Fam Physician. 1996 May;42:8488688683
Comment In: Can Fam Physician. 1996 Jun;42:1088-908704481
PubMed ID
8924805 View in PubMed
Less detail

The 2005 British Columbia smoking cessation mass media campaign and short-term changes in smokers attitudes.

https://arctichealth.org/en/permalink/ahliterature158616
Source
J Health Commun. 2008 Mar;13(2):125-48
Publication Type
Article
Date
Mar-2008
Author
Lynda Gagné
Author Affiliation
School of Public Administration, University of Victoria, Victoria BC, Canada. lgagne@uvic.ca
Source
J Health Commun. 2008 Mar;13(2):125-48
Date
Mar-2008
Language
English
Publication Type
Article
Keywords
Adult
Age Factors
Attitude to Health
British Columbia
Female
Health Behavior
Health promotion
Health Surveys
Humans
Male
Mass Media
Program Development
Prospective Studies
Psychometrics
Risk-Taking
Smoking
Smoking Cessation - methods
Social Marketing
Time Factors
Abstract
The effect of the 2005 British Columbia (BC) smoking cessation mass media campaign on a panel (N = 1,341) of 20-30-year-old smokers' attitudes is evaluated. The 5-week campaign consisted of posters, television, and radio ads about the health benefits of cessation. Small impacts on the panel's attitudes toward the adverse impacts of smoking were found, with greater impacts found for those who had no plans to quit smoking at the initial interview. As smokers with no plans to quit increasingly recognized the adverse impacts of smoking, they also increasingly agreed that they use smoking as a coping mechanism. Smokers with plans to quit at the initial interview already were well aware of smoking's adverse impacts. Respondents recalling the campaign poster, which presented a healthy alternative to smoking, decreased their perception of smoking as a coping mechanism and devalued their attachment to smoking. Evidence was found that media ad recall mediates unobserved predictors of attitudes toward smoking.
PubMed ID
18300065 View in PubMed
Less detail

The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of risk.

https://arctichealth.org/en/permalink/ahliterature151165
Source
Can J Cardiol. 2009 May;25(5):279-86
Publication Type
Article
Date
May-2009
Author
Raj S Padwal
Brenda R Hemmelgarn
Nadia A Khan
Steven Grover
Donald W McKay
Thomas Wilson
Brian Penner
Ellen Burgess
Finlay A McAlister
Peter Bolli
Machael D Hill
Jeff Mahon
Martin G Myers
Carl Abbott
Ernesto L Schiffrin
George Honos
Karen Mann
Guy Tremblay
Alain Milot
Lyne Cloutier
Arun Chockalingam
Simon W Rabkin
Martin Dawes
Rhian M Touyz
Chaim Bell
Kevin D Burns
Marcel Ruzicka
Norman R C Campbell
Michel Vallée
Ramesh Prasad
Marcel Lebel
Sheldon W Tobe
Author Affiliation
Division of General Internal Medicine, University of Alberta, Edmonton, Canada. rpadwal@ualberta.ca
Source
Can J Cardiol. 2009 May;25(5):279-86
Date
May-2009
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antihypertensive Agents - therapeutic use
Blood Pressure Determination - standards
Canada
Clinical Competence
Combined Modality Therapy
Education, Medical, Continuing - standards
Female
Guideline Adherence
Health Promotion - organization & administration
Humans
Hypertension - diagnosis - therapy
Life Style
Male
Middle Aged
Prognosis
Randomized Controlled Trials as Topic
Risk Management
Treatment Outcome
Abstract
To provide updated, evidence-based recommendations for the diagnosis and assessment of adults with hypertension.
The diagnosis of hypertension is dependent on appropriate blood pressure measurement, the timely assessment of serially elevated readings, the degree of blood pressure elevation, the method of measurement (office, ambulatory, home) and associated comorbidities. The presence of cardiovascular risk factors and target organ damage should be ascertained to assess global cardiovascular risk and determine the urgency, intensity and type of treatment required.
MEDLINE searches were conducted from November 2007 to October 2008 with the aid of a medical librarian. Reference lists were scanned, experts were contacted, and the personal files of authors and subgroup members were used to identify additional studies. Content and methodological experts assessed studies using prespecified, standardized evidence-based algorithms. Recommendations were based on evidence from peer-reviewed full-text articles only.
Recommendations for blood pressure measurement, criteria for hypertension diagnosis and follow-up, assessment of global cardiovascular risk, diagnostic testing, diagnosis of renovascular and endocrine causes of hypertension, home and ambulatory monitoring, and the use of echocardiography in hypertensive individuals are outlined. Key messages include continued emphasis on the expedited, accurate diagnosis of hypertension, the importance of global risk assessment and the need for ongoing monitoring of hypertensive patients to identify incident type 2 diabetes.
All recommendations were graded according to strength of the evidence and voted on by the 57 members of the Canadian Hypertension Education Program Evidence-Based Recommendations Task Force. All recommendations were required to be supported by at least 70% of task force members. These guidelines will continue to be updated annually.
Notes
Cites: Diabetes Care. 2004 Jan;27(1):247-5514693997
Cites: JAMA. 2008 Jul 9;300(2):197-20818612117
Cites: Hypertension. 2004 May;43(5):963-915037557
Cites: Pediatrics. 2004 Aug;114(2 Suppl 4th Report):555-7615286277
Cites: Lancet. 2004 Sep 11-17;364(9438):937-5215364185
Cites: Circulation. 1991 Jan;83(1):356-621984895
Cites: JAMA. 1996 May 22-29;275(20):1571-68622248
Cites: Arch Intern Med. 1996 Jul 8;156(13):1414-208678709
Cites: Arch Intern Med. 1998 Mar 23;158(6):655-629521231
Cites: Am J Cardiol. 2005 Jan 1;95(1):29-3515619390
Cites: Can J Cardiol. 2005 Jun;21(8):645-5616003448
Cites: Can J Cardiol. 2006 May 15;22(7):559-6416755310
Cites: Can J Cardiol. 2006 May 15;22(7):573-8116755312
Cites: Can J Cardiol. 2006 May 15;22(7):606-1316755316
Cites: N Engl J Med. 2006 Oct 12;355(15):1551-6216980380
Cites: Arch Intern Med. 2006 Nov 13;166(20):2191-20117101936
Cites: Lancet. 2007 Jan 20;369(9557):201-717240286
Cites: AJR Am J Roentgenol. 2007 Mar;188(3):798-81117312071
Cites: Can J Cardiol. 2007 May 15;23(7):529-3817534459
Cites: Can J Cardiol. 2007 May 15;23(7):539-5017534460
Cites: J Hypertens. 2007 Jun;25(6):1311-717563546
Cites: Kidney Int. 2007 Aug;72(3):260-417507905
Cites: Hypertension. 2007 Sep;50(3):467-7317679652
Cites: Am Heart J. 2000 Feb;139(2 Pt 1):272-8110650300
Cites: N Engl J Med. 2000 Mar 30;342(13):905-1210738048
Cites: Clin Radiol. 2000 May;55(5):346-5310816399
Cites: Can J Cardiol. 2000 Sep;16(9):1094-10211021953
Cites: JAMA. 2001 Jul 11;286(2):180-711448281
Cites: Clin Sci (Lond). 2001 Dec;101(6):671-911724655
Cites: Stroke. 2002 Jul;33(7):1776-8112105351
Cites: Lancet. 2002 Dec 14;360(9349):1903-1312493255
Cites: Lancet. 2003 Apr 5;361(9364):1149-5812686036
Cites: Eur Heart J. 2003 Jun;24(11):987-100312788299
Cites: Lancet. 2003 Nov 29;362(9398):1776-714654312
Cites: Arch Intern Med. 2007 Nov 26;167(21):2296-30318039987
Cites: Can J Cardiol. 2008 Jun;24(6):455-6318548142
Cites: Can J Cardiol. 2008 Jun;24(6):465-7518548143
Cites: Hypertension. 2004 Jan;43(1):10-714638619
PubMed ID
19417858 View in PubMed
Less detail

The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy.

https://arctichealth.org/en/permalink/ahliterature151164
Source
Can J Cardiol. 2009 May;25(5):287-98
Publication Type
Article
Date
May-2009
Author
Nadia A Khan
Brenda Hemmelgarn
Robert J Herman
Chaim M Bell
Jeff L Mahon
Lawrence A Leiter
Simon W Rabkin
Michael D Hill
Raj Padwal
Rhian M Touyz
Pierre Larochelle
Ross D Feldman
Ernesto L Schiffrin
Norman R C Campbell
Gordon Moe
Ramesh Prasad
Malcolm O Arnold
Tavis S Campbell
Alain Milot
James A Stone
Charlotte Jones
Richard I Ogilvie
Pavel Hamet
George Fodor
George Carruthers
Kevin D Burns
Marcel Ruzicka
Jacques DeChamplain
George Pylypchuk
Robert Petrella
Jean-Martin Boulanger
Luc Trudeau
Robert A Hegele
Vincent Woo
Phil McFarlane
Michel Vallée
Jonathan Howlett
Simon L Bacon
Patrice Lindsay
Richard E Gilbert
Richard Z Lewanczuk
Sheldon Tobe
Author Affiliation
Division of General Internal Medicine, University of British Columbia, Vancouver, Canada. nakhan@shaw.ca
Source
Can J Cardiol. 2009 May;25(5):287-98
Date
May-2009
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antihypertensive Agents - therapeutic use
Blood Pressure Determination - standards
Canada
Case Management - standards
Combined Modality Therapy
Diet, Sodium-Restricted
Female
Health Promotion - organization & administration
Humans
Hypertension - diagnosis - therapy
Life Style
Male
Middle Aged
Patient Education as Topic
Prognosis
Program Evaluation
Randomized Controlled Trials as Topic
Treatment Outcome
Abstract
To update the evidence-based recommendations for the prevention and management of hypertension in adults for 2009.
For lifestyle and pharmacological interventions, evidence from randomized controlled trials and systematic reviews of trials was preferentially reviewed. Changes in cardiovascular morbidity and mortality were the primary outcomes of interest. However, for lifestyle interventions, blood pressure lowering was accepted as a primary outcome given the lack of long-term morbidity and mortality data in this field. Progression of kidney dysfunction was also accepted as a clinically relevant primary outcome among patients with chronic kidney disease.
A Cochrane collaboration librarian conducted an independent MEDLINE search from 2007 to August 2008 to update the 2008 recommendations. To identify additional published studies, reference lists were reviewed and experts were contacted. All relevant articles were reviewed and appraised independently by both content and methodological experts using prespecified levels of evidence.
For lifestyle modifications to prevent and treat hypertension, restrict dietary sodium to less than 2300 mg (100 mmol)/day (and 1500 mg to 2300 mg [65 mmol to 100 mmol]/day in hypertensive patients); perform 30 min to 60 min of aerobic exercise four to seven days per week; maintain a healthy body weight (body mass index 18.5 kg/m(2) to 24.9 kg/m(2)) and waist circumference (smaller than 102 cm for men and smaller than 88 cm for women); limit alcohol consumption to no more than 14 units per week in men or nine units per week in women; follow a diet that is reduced in saturated fat and cholesterol, and that emphasizes fruits, vegetables and low-fat dairy products, dietary and soluble fibre, whole grains and protein from plant sources; and consider stress management in selected individuals with hypertension. For the pharmacological management of hypertension, treatment thresholds and targets should be predicated on by the patient's global atherosclerotic risk, target organ damage and comorbid conditions. Blood pressure should be decreased to lower than 140/90 mmHg in all patients, and to lower than 130/80 mmHg in those with diabetes mellitus or chronic kidney disease. Most patients will require more than one agent to achieve these target blood pressures. Antihypertensive therapy should be considered in all adult patients regardless of age (caution should be exercised in elderly patients who are frail). For adults without compelling indications for other agents, initial therapy should include thiazide diuretics. Other agents appropriate for first-line therapy for diastolic and/or systolic hypertension include angiotensin- converting enzyme (ACE) inhibitors (in patients who are not black), long-acting calcium channel blockers (CCBs), angiotensin receptor antagonists (ARBs) or beta-blockers (in those younger than 60 years of age). A combination of two first-line agents may also be considered as the initial treatment of hypertension if the systolic blood pressure is 20 mmHg above the target or if the diastolic blood pressure is 10 mmHg above the target. The combination of ACE inhibitors and ARBs should not be used. Other agents appropriate for first-line therapy for isolated systolic hypertension include long- acting dihydropyridine CCBs or ARBs. In patients with angina, recent myocardial infarction or heart failure, beta-blockers and ACE inhibitors are recommended as first-line therapy; in patients with cerebrovascular disease, an ACE inhibitor/diuretic combination is preferred; in patients with proteinuric nondiabetic chronic kidney disease, ACE inhibitors or ARBs (if intolerant to ACE inhibitors) are recommended; and in patients with diabetes mellitus, ACE inhibitors or ARBs (or, in patients without albuminuria, thiazides or dihydropyridine CCBs) are appropriate first-line therapies. All hypertensive patients with dyslipidemia should be treated using the thresholds, targets and agents outlined in the Canadian Cardiovascular Society position statement (recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease). Selected high-risk patients with hypertension who do not achieve thresholds for statin therapy according to the position paper should nonetheless receive statin therapy. Once blood pressure is controlled, acetylsalicylic acid therapy should be considered.
All recommendations were graded according to strength of the evidence and voted on by the 57 members of the Canadian Hypertension Education Program Evidence-Based Recommendations Task Force. All recommendations reported here achieved at least 95% consensus. These guidelines will continue to be updated annually.
Notes
Cites: Circulation. 2000 Jun 6;101(22):2612-710840013
Cites: Lancet. 1999 Nov 20;354(9192):1751-610577635
Cites: JAMA. 2001 Jan 24-31;285(4):437-4311242428
Cites: Can J Cardiol. 2001 May;17(5):543-5911381277
Cites: Lancet. 2001 Sep 29;358(9287):1033-4111589932
Cites: N Engl J Med. 2001 Dec 6;345(23):1667-7511759645
Cites: Can J Cardiol. 2002 Jun;18(6):625-4112107420
Cites: Am J Med. 2002 Oct 1;113(5):359-6412401529
Cites: Lancet. 2003 Apr 5;361(9364):1149-5812686036
Cites: JAMA. 2003 May 21;289(19):2534-4412759325
Cites: J Am Coll Cardiol. 2003 Jun 18;41(12):2197-20412821247
Cites: Lancet. 2003 Sep 6;362(9386):767-7113678869
Cites: BMJ. 2004 Feb 7;328(7435):32614744823
Cites: Can J Cardiol. 2004 Jan;20(1):41-5414968142
Cites: Can J Cardiol. 2004 Jan;20(1):55-914968143
Cites: CMAJ. 1992 Jun 1;146(11):1997-20051596849
Cites: Am J Cardiol. 1998 Oct 16;82(8A):2N-9N9809895
Cites: Am J Kidney Dis. 1998 Nov;32(5 Suppl 3):S112-99820470
Cites: Lancet. 1999 Feb 20;353(9153):611-610030325
Cites: Lancet. 1999 Mar 6;353(9155):793-610459960
Cites: Ann Intern Med. 2004 Nov 16;141(10):781-815545678
Cites: BMC Cardiovasc Disord. 2005;5(1):415691376
Cites: J Am Coll Cardiol. 2005 Mar 1;45(5):712-915734615
Cites: Stroke. 2005 Jun;36(6):1218-2615879332
Cites: Can J Cardiol. 2005 Jun;21(8):657-7216003449
Cites: J Hypertens. 2005 Dec;23(12):2157-7216269957
Cites: Can J Cardiol. 2005 Dec;21(14):1265-7116341294
Cites: J Am Soc Nephrol. 2006 Mar;17(3 Suppl 1):S1-2716497879
Cites: J Cardiovasc Med (Hagerstown). 2006 Jan;7(1):29-3816645357
Cites: Can J Cardiol. 2006 May 15;22(7):559-6416755310
Cites: Can J Cardiol. 2006 May 15;22(7):583-9316755313
Cites: J Am Geriatr Soc. 2007 Mar;55(3):383-817341240
Cites: Lancet. 2007 Sep 8;370(9590):829-4017765963
Cites: Ann Intern Med. 2008 Jan 1;148(1):30-4817984482
Cites: Am J Ther. 2008 Jan-Feb;15(1):36-4318223352
Cites: Am J Hypertens. 2008 Feb;21(2):148-5218174885
Cites: J Hypertens. 2008 Mar;26(3):403-1118300848
Cites: J Hypertens. 2008 Apr;26(4):672-718327075
Cites: N Engl J Med. 2008 Apr 10;358(15):1547-5918378520
Cites: N Engl J Med. 2008 May 1;358(18):1887-9818378519
Cites: Lancet. 2008 May 10;371(9624):1575-618468534
Cites: Hypertension. 2008 Jun;51(6):1552-618391094
Cites: J Intern Med. 2008 Aug;264(2):187-9418393959
Cites: Lancet. 2008 Aug 16;372(9638):547-5318707986
Cites: N Engl J Med. 2008 Sep 18;359(12):1225-3718753639
Cites: Lancet. 2008 Sep 27;372(9644):1174-8318757085
Cites: Lancet. 2000 Dec 9;356(9246):1955-6411130523
PubMed ID
19417859 View in PubMed
Less detail

2009 Canadian Hypertension Education Program recommendations: the scientific summary--an annual update.

https://arctichealth.org/en/permalink/ahliterature151166
Source
Can J Cardiol. 2009 May;25(5):271-7
Publication Type
Article
Date
May-2009
Author
Norman R C Campbell
Nadia A Khan
Michael D Hill
Guy Tremblay
Marcel Lebel
Janusz Kaczorowski
Finlay A McAlister
Richard Z Lewanczuk
Sheldon Tobe
Author Affiliation
Department of Medicine, University of Calgary, Calgary, Canada. ncampbel@ucalgary.ca
Source
Can J Cardiol. 2009 May;25(5):271-7
Date
May-2009
Language
English
Publication Type
Article
Keywords
Antihypertensive Agents - therapeutic use
Attitude to Health
Blood Pressure Determination
Canada
Combined Modality Therapy
Diet, Sodium-Restricted
Female
Health Knowledge, Attitudes, Practice
Health Promotion - organization & administration
Humans
Hypertension - diagnosis - therapy
Life Style
Male
Patient Education as Topic
Program Evaluation
Randomized Controlled Trials as Topic
Severity of Illness Index
Abstract
The present report highlights the key messages of the 2009 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension and the supporting clinical evidence. In 2009, the CHEP emphasizes the need to improve the control of hypertension in people with diabetes. Intensive reduction in blood pressure (to less than 130/80 mmHg) in people with diabetes leads to significant reductions in mortality rates, disability rates and overall health care system costs, and may lead to improved quality of life. The CHEP recommendations continue to emphasize the important role of patient self-efficacy by promoting lifestyle changes to prevent and control hypertension, and encouraging home measurement of blood pressure. Unfortunately, most Canadians make only minor changes in lifestyle after a diagnosis of hypertension. Routine blood pressure measurement at all appropriate visits, and screening for and management of all cardiovascular risks are key to blood pressure management. Many young hypertensive Canadians with multiple cardiovascular risks are not treated with antihypertensive drugs. This is despite the evidence that individuals with multiple cardiovascular risks and hypertension should be strongly considered for antihypertensive drug therapy regardless of age. In 2009, the CHEP specifically recommends not to combine an angiotensin-converting enzyme inhibitor with an angiotensin receptor blocker in people with uncomplicated hypertension, diabetes (without micro- or macroalbuminuria), chronic kidney disease (without nephropathy [micro- or overt proteinuria]) or ischemic heart disease (without heart failure).
Notes
Cites: N Engl J Med. 2000 Jan 20;342(3):145-5310639539
Cites: Lancet. 2008 Aug 16;372(9638):547-5318707986
Cites: Hypertension. 2001 Apr;37(4):1053-911304502
Cites: N Engl J Med. 2001 Sep 20;345(12):851-6011565517
Cites: N Engl J Med. 2001 Sep 20;345(12):861-911565518
Cites: Lancet. 2001 Sep 29;358(9287):1033-4111589932
Cites: Kidney Int. 2002 Mar;61(3):1086-9711849464
Cites: Ann Intern Med. 2002 Apr 2;136(7):493-50311926784
Cites: N Engl J Med. 2008 Sep 18;359(12):1225-3718753639
Cites: Lancet. 2008 Sep 27;372(9644):1174-8318757085
Cites: Hypertension. 2009 Feb;53(2):128-3419114646
Cites: JAMA. 2002 May 15;287(19):2542-5112020335
Cites: J Hypertens. 2002 Jul;20(7):1255-712131513
Cites: JAMA. 2003 Apr 23-30;289(16):2083-9312709466
Cites: Lancet. 2003 Sep 6;362(9386):767-7113678869
Cites: Lancet. 2003 Sep 6;362(9386):782-813678872
Cites: Stroke. 2003 Nov;34(11):2741-814576382
Cites: Cochrane Database Syst Rev. 2004;(3):CD00493715266549
Cites: BMJ. 1994 Jan 29;308(6924):313-208124121
Cites: Arch Intern Med. 1997 Mar 24;157(6):657-679080920
Cites: JAMA. 1997 Apr 2;277(13):1039-459091691
Cites: N Engl J Med. 1997 Apr 17;336(16):1117-249099655
Cites: JAMA. 1997 Dec 3;278(21):1759-669388153
Cites: Lancet. 1998 Jun 13;351(9118):1755-629635947
Cites: BMJ. 1998 Sep 12;317(7160):703-139732337
Cites: N Engl J Med. 1999 Mar 4;340(9):677-8410053176
Cites: N Engl J Med. 2004 Nov 11;351(20):2058-6815531767
Cites: Arch Intern Med. 2005 Jun 27;165(12):1410-915983291
Cites: Can J Cardiol. 2006 Jan;22(1):23-4516450016
Cites: Ann Intern Med. 2006 Apr 4;144(7):485-9516585662
Cites: Can J Cardiol. 2007 May 1;23(6):437-4317487286
Cites: Lancet. 2007 Sep 8;370(9590):829-4017765963
Cites: CMAJ. 2007 Oct 9;177(8):859-6517923653
Cites: Can J Cardiol. 2008 Mar;24(3):199-20418340389
Cites: N Engl J Med. 2008 Apr 10;358(15):1547-5918378520
Cites: N Engl J Med. 2008 May 1;358(18):1887-9818378519
Cites: Lancet. 2008 May 10;371(9624):1575-618468534
Cites: CMAJ. 2008 May 20;178(11):1441-918490640
Cites: CMAJ. 2008 May 20;178(11):1458-6018490641
Cites: Can J Cardiol. 2008 Jun;24(6):485-9018548146
Cites: Can J Cardiol. 2008 Jun;24(6):497-118548148
Cites: N Engl J Med. 2008 Jun 12;358(24):2560-7218539916
Cites: Lancet. 2000 Jan 22;355(9200):253-910675071
PubMed ID
19417857 View in PubMed
Less detail

2010 Canadian Hypertension Education Program (CHEP) recommendations: the scientific summary - an update of the 2010 theme and the science behind new CHEP recommendations.

https://arctichealth.org/en/permalink/ahliterature143446
Source
Can J Cardiol. 2010 May;26(5):236-40
Publication Type
Article
Date
May-2010
Author
Norman R C Campbell
Janusz Kaczorowski
Richard Z Lewanczuk
Ross Feldman
Luc Poirier
Margaret Moy Kwong
Marcel Lebel
Finlay A McAlister
Sheldon W Tobe
Author Affiliation
Department of Medicine, University of Calgary, Alberta. ncampbel@ucalgary.ca
Source
Can J Cardiol. 2010 May;26(5):236-40
Date
May-2010
Language
English
Publication Type
Article
Keywords
Antihypertensive Agents - administration & dosage
Canada
Diet, Sodium-Restricted
Female
Health promotion
Humans
Hypertension - prevention & control - therapy
Life Style
Male
Patient Education as Topic
Practice Guidelines as Topic
Randomized Controlled Trials as Topic
Risk Reduction Behavior
Abstract
The present article is a summary of the theme, the key recommendations for management of hypertension and the supporting clinical evidence of the 2010 Canadian Hypertension Education Program (CHEP). In 2010, CHEP emphasizes the need for health care professionals to stay informed about hypertension through automated updates at www.htnupdate.ca. A new interactive Internet-based lecture series will be available in 2010 and a program to train community hypertension leaders will be expanded. Patients can also sign up to receive regular updates in a pilot program at www.myBPsite.ca. In 2010, the new recommendations include consideration for using automated office blood pressure monitors, new targets for dietary sodium for the prevention and treatment of hypertension that are aligned with the national adequate intake values, and recommendations for considering treatment of selected hypertensive patients at high risk with calcium channel blocker/angiotensin-converting enzyme inhibitor combinations and the use of angiotensin receptor blockers.
Notes
Cites: CMAJ. 1999 Jan 12;160(1):31-79934341
Cites: Lancet. 2007 Dec 15;370(9604):2044-5318063027
Cites: BMC Cardiovasc Disord. 2005;5(1):1815985180
Cites: J Hum Hypertens. 2005 Aug;19(8):607-1315920457
Cites: Blood Press Monit. 2005 Oct;10(5):257-6216205444
Cites: Blood Press Monit. 2006 Apr;11(2):59-6216534406
Cites: Hypertension. 2006 Nov;48(5):853-6016982958
Cites: Am J Hypertens. 2008 Mar;21(3):280-318219304
Cites: Can J Cardiol. 2008 Apr;24(4):269-7318401466
Cites: N Engl J Med. 2008 Apr 10;358(15):1547-5918378520
Cites: CMAJ. 2008 May 20;178(11):1441-918490640
Cites: Can J Cardiol. 2008 Jun;24(6):507-1218548150
Cites: Lancet. 2008 Aug 16;372(9638):547-5318707986
Cites: N Engl J Med. 2008 Sep 18;359(12):1225-3718753639
Cites: Can Fam Physician. 2008 Oct;54(10):1418-2318854471
Cites: Lancet. 2008 Sep 27;372(9644):1174-8318757085
Cites: N Engl J Med. 2008 Dec 4;359(23):2417-2819052124
Cites: Hypertension. 2009 Feb;53(2):128-3419114646
Cites: PLoS Med. 2009 Apr 28;6(4):e100005819399161
Cites: Can J Cardiol. 2009 May;25(5):287-9819417859
Cites: J Hypertens. 2009 Jun;27(6):1136-5119451836
Cites: Hypertension. 2009 Sep;54(3):444-619620515
Cites: Hypertension. 2010 Feb;55(2):399-40720026768
Cites: J Clin Hypertens (Greenwich). 2007 Apr;9(4):267-7017396069
Cites: J Hum Hypertens. 2007 Jul;21(7):588-9017377600
Cites: Can J Cardiol. 2005 May 15;21(7):589-9315940357
PubMed ID
20485687 View in PubMed
Less detail

The Ability of Posters to Enhance the Comfort Level with Breastfeeding in a Public Venue in Rural Newfoundland and Labrador.

https://arctichealth.org/en/permalink/ahliterature279830
Source
J Hum Lact. 2016 Feb;32(1):174-81
Publication Type
Article
Date
Feb-2016
Author
Alissa Vieth
Janine Woodrow
Janet Murphy-Goodridge
Courtney O'Neil
Barbara Roebothan
Source
J Hum Lact. 2016 Feb;32(1):174-81
Date
Feb-2016
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Aged, 80 and over
Attitude to Health
Audiovisual Aids
Breast Feeding - psychology
Cross-Sectional Studies
Female
Health Promotion - methods
Humans
Male
Middle Aged
Newfoundland and Labrador
Public Opinion
Rural Population
Surveys and Questionnaires
Young Adult
Abstract
The acceptance and support of breastfeeding in public venues can influence breastfeeding practices and, ultimately, the health of the population.
The primary aim of this study was to investigate whether posters targeted at the general public could improve acceptability of breastfeeding in public places.
A convenience sample of 255 participants was surveyed at shopping centers in 2 rural communities of Newfoundland and Labrador. Experimentally, questions were posed to 117 participants pre- and post-exposure to 2 specific posters designed to promote public acceptance of breastfeeding in public.
Initially, we surveyed that only 51.9% of participants indicated that they were comfortable with a woman breastfeeding anywhere in public. However, context played a role, whereby a doctor's office (84.5%) or park (81.4%) were the most acceptable public places for breastfeeding, but least acceptable was a business office environment (66.7%). Of participants, 35.4% indicated previously viewing specific posters. We used a visual analog scale to test poster viewing on the acceptability of public breastfeeding in the context of a doctor's office and a restaurant. Results of pre- versus post-viewing of the promotional posters indicated significant improvements in both scenarios: in a doctor's office (P = .035) and in a restaurant (P = .021).
Nearly 50% of the surveyed population indicated discomfort with a mother breastfeeding in public. Both cross-sectional and interventional evidence showed that posters significantly improved the reported level of comfort toward seeing breastfeeding in public.
PubMed ID
26151965 View in PubMed
Less detail

Aboriginal grandmothers' experience with health promotion and participatory action research.

https://arctichealth.org/en/permalink/ahliterature198754
Source
Qual Health Res. 2000 Mar;10(2):188-213
Publication Type
Article
Date
Mar-2000
Author
G. Dickson
Author Affiliation
College of Nursing, University of Saskatchewan, Canada.
Source
Qual Health Res. 2000 Mar;10(2):188-213
Date
Mar-2000
Language
English
Publication Type
Article
Keywords
Aged
American Native Continental Ancestry Group
Female
Health Knowledge, Attitudes, Practice
Health promotion
Health Services Research
Humans
Middle Aged
Saskatchewan
Abstract
This article describes a case study examining the effects of participating in a health promotion project, one aspect of which was a health assessment conducted using participatory action research. The study was carried out over 2.5 years in a project for older Aboriginal women (hereafter known as the grandmothers). Participation in the project and health assessment contributed to a number of changes in them, which were categorized as cleansing and healing, connecting with self, acquiring knowledge and skills, connecting within the group, and external exposure and engagement. This experience demonstrated an approach to health promotion programming and conducting a health assessment that was acceptable to this group of people and fostered changes congruent with empowerment.
PubMed ID
10788283 View in PubMed
Less detail

1642 records – page 1 of 165.